| Smad3 is unlikely to function as a classical tumor suppressor gene in the pathogenesis of sporadic parathyroid or enteropancreatic endocrine tumors. | pancreatic,thyroid, |
| Smad3 expression may have a critical role in tumor suppression in the early stages of gastric carcinogenesis. | gastric, |
| Enhanced TGF-beta1-induced Smad2 and -3 signaling in prostate cancer cells may correlate with tumor suppressive activity. | prostate, |
| these findings support the notion that Smad3 has important tumor suppressor function for breast cancer | breast, |
| Smad3 mediates regulation of growth control genes to senescence in vitro and tumor suppression in vivo. | None |
| Smad3 enables the tumor suppression function of TGF-beta by serving as a physiological mediator of TGF-beta-induced apoptosis. | None |
| Thus, SMCX is a novel Smad3 corepressor that may antagonize the tumor suppressing activity of the TGF-beta/Smad3 signaling pathway and thereby contribute to tumorigenesis. | None |
| Smad3 is identified as a key factor to trigger TGFbeta-regulated events and ascribe tumor suppressor as well as oncogenic activities to this protein. | None |
| Hepatitis B virus X protein shifts hepatocytic TGF-beta signaling from the tumor-suppressive pSmad3C pathway to the oncogenic pSmad3L pathway in early carcinogenic process. | None |
| Oncogenic Smad3 signaling induced by chronic inflammation is an early event in ulcerative colitis-associated carcinogenesis. | None |